EUCTR2006-004260-31-GB进行中（未招募）1 期
An open label study of humira (adalimumab)in the treatment of patients with severe psoriasis - Open label study of humira in patients with severe psoriasis version 1
HL NHS Trust0 个研究点开始时间: 2007年1月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patients aged 18 - 80 years
- •2.Patients with severe psoriasis, defined as a PASI of 10 or more or involvement of 10% or more of body surface area, who are unresponsive/intolerant/have contraindications to ultraviolet light therapy and at least 3 other second line therapies.
- •3.Patients who provide written informed consent.
- •4.Patients who are not currently receiving oral therapy or phototherapy for their psoriasis, and have not received any of these treatments within the previous 28 days.
- •5.Females of childbearing potential who provide a negative urine pregnancy test and are willing to use adequate contraception for the duration of the treatment and for at least 5 months after discontinuation of treatment.
- •6.Sexually active males who are willing to use adequate contraception for the duration of the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years)
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Pregnant or breast-feeding females.
- •2.Patients with current or previous recurrent infections, including hepatitis, chronic leg ulcers, recurrent cellulitis and persistent or recurrent chest infections. There have been reports of serious infections in patients on humira.
- •3.Patients with active or latent tuberculosis (TB) There have been reports of development or reactivation of TB in patients treated with humira.
- •4.Patients with an abnormal chest x-ray.
- •5.Patients over the age of 65 years, or diabetics who have not been vaccinated against influenza and pneumococcus, because of the increased risk of infection in such patients.
- •6.Patients who are Hepatitis B or C positive. The safety of TNF antagonists in patients with chronic hepatitis is not known.
- •7.Patients with significantly abnormal liver function tests. Humira can cause abnormalities of liver function tests.
- •8.Patients who are HIV positive.
- •9.Patients with current or previous malignancy, excepting non-melanoma skin cancer. In clinical trials of TNF antagonists in patients with rheumatoid arthritis, more cases of lymphoma were observed compared with controls. However there is an increased background lymphoma risk in patients with rheumatoid arthritis, but these data cannot exclude a possible risk of malignancy in patients treated with humira.
- •10.Patients with pre-existing or recent onset of demyelinating disorders. Humira has been associated, in rare cases, with exacerbation of clinical symptoms and/or radiographic evidence of demyelinating disease, such as multiple sclerosis.
- •11.Patients with signs and symptoms of heart failure (New York Heart Association grade 3 or 4). Humira has been associated with the development or exacerbation of heart failure.
- •12.Patients who have significant hypercholesterolaemia. Humira can cause hypercholesterolaemia.
- •12.Patients who have any condition which would interfere with their ability to participate in the study.
- •14.Patients who are unable to read or understand the informed consent or follow verbal and/or written instructions.
研究者
相似试验
已完成
3 期
Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or PhototherapyPsoriasisNCT00566722Abbott152
撤回
2 期
Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma GangrenosumPyoderma GangrenosumNCT00690846Wake Forest University Health Sciences
已完成
不适用
Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis PatientsNon-infectious Intermediate, Posterior and PanuveitisNCT03339102AbbVie158
已完成
3 期
Efficacy of MabAsia (Adalimumab) in Rheumatoid ArthritisRheumatoid Arthritis.Seropositive Rheumatoid ArthritisIRCT2014090319025N1Vice Chancellor for research, Tehran University of Medical Sciences105
进行中（未招募）
不适用
EFFICACY AND SAFETY OF ADALIMUMAB (HUMIRA®) IN PATIENTS WITH PERIPHERAL SPONDYLOARTHRITIS WITHOUT ANKYLOSING SPONDYLITIS OR PSORIATIC ARTHRITISPERIPHERAL SPONDYLOARTHRITIS WITHOUT ANKYLOSING SPONDYLITIS OR PSORIATIC ARTHRITISMedDRA version: 9.1Level: LLTClassification code 10051265Term: SpondyloarthropathyEUCTR2008-006885-27-NLClinical Immunology and Rheumatology